• Enhanced Sensitivity: We address the challenge of detecting trace biomarkers at extremely low concentrations by developing high-resolution, high-sensitivity micropore chips. These tools are designed to identify subtle cellular shape and size abnormalities with unparalleled precision.

• Noise Reduction: Our solutions mitigate background noise to ensure reliable detection, even for the most elusive single-molecule targets.

• Integration into User-Friendly Systems: By combining advanced hardware with intuitive software, we simplify workflows and make single-molecule sensing accessible for research and clinical applications.

• Compact and Precise Systems: Leveraging the Coulter counter principle with solid-state micropores, we are trying to create compact systems capable of performing highly accurate complete blood counts. These systems provide precise population distributions for improved diagnostics.

• Point-of-Care Readiness: We are designing solutions for healthcare centres, reducing throughput times and enabling rapid diagnostics in resource-constrained settings.

• Adaptability: The technology is targeted to be optimized to handle diverse sample types and varying conditions, ensuring consistent and reliable performance in real-world scenarios

We aim to tackle the complexities of diagnosing genetic and hereditary diseases by developing innovative solutions focused on precision and accessibility.

• Precise DNA Sequence Detection: Identifying specific gene sequences with high accuracy is crucial for diagnosing hereditary diseases. We are developing CRISPR-based detection methods to enable highly targeted identification of these sequences, ensuring reliable and precise results.

• Faster and Economical Early Diagnosis: Many genetic conditions go undetected until symptoms become apparent, limiting treatment options. Our advanced detection methods offer a faster, more cost-effective alternative to complete gene sequencing, enabling earlier diagnosis and timely intervention.

• Enhancing Accessibility: By focusing on scalable solutions, we strive to make cutting-edge genetic diagnostics available to a broader range of healthcare settings, ensuring that these advancements benefit as many patients as possible.

Image reference: Wayne Yang, Laura Restrepo-Pérez, Michel Bengtson, Stephanie J. Heerema, Anthony Birnie, Jaco van der Torre, and Cees Dekker

Nano Letters 2018 18 (10), 6469-6474

DOI: 10.1021/acs.nanolett.8b02968